Prospects of β‐Secretase Inhibitors for the Treatment of Alzheimer’s Disease
Authors:
- 3 July 2015
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 10 (9) , 1463-1466
Abstract
β‐Secretase continues to be an attractive drug discovery target for the therapeutic intervention of Alzheimer’s disease (AD). This enzyme plays a critical role in the production of neurotoxic β‐amyloid (Aβ) peptides in the brain. Over the years, extensive research efforts have led to the development of many promising classes of inhibitors against this protease. Many small‐molecule, peptidomimetic, and nonpeptide β‐secretase inhibitors have now overcome the key challenging development hurdles such as selectivity and brain penetration. A number of inhibitors have also shown further promise in reducing brain Aβ and rescuing cognitive decline in animal models. Recently, several β‐secretase inhibitors have entered into preclinical and phase I studies, and at least one of these inhibitors has advanced to phase II/III human trials. The outlook on β‐secretase inhibitor drugs for the treatment of AD patients is discussed herein.Keywords
This publication has 28 references indexed in Scilit:
- Three dimensions of the amyloid hypothesis: time, space and 'wingmen'Nature Neuroscience, 2015
- Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanismMolecular Neurodegeneration, 2014
- Developing β‐secretase inhibitors for treatment of Alzheimer’s diseaseJournal of Neurochemistry, 2011
- β‐Secretase inhibitor GRL‐8234 rescues age‐related cognitive decline in APP transgenic miceThe FASEB Journal, 2010
- γ-Secretase Inhibition and Modulation for Alzheimers DiseaseCurrent Alzheimer Research, 2008
- Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic MiceJournal of Biological Chemistry, 2007
- Alzheimer therapeutics—what after the cholinesterase inhibitors?Age and Ageing, 2006
- BACE1, a Major Determinant of Selective Vulnerability of the Brain to Amyloid-β Amyloidogenesis, is Essential for Cognitive, Emotional, and Synaptic FunctionsThe Journal of Neuroscience, 2005
- BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's DiseaseNeuron, 2004
- Translating cell biology into therapeutic advances in Alzheimer's diseaseNature, 1999